Oral administration of garlic-derived nanoparticles improves cancer immunotherapy by inducing intestinal IFNγ-producing γδ T cells
Source abstract
Abstract
Gamma-delta (γδ) T cell-based cancer immunotherapies represent a promising avenue for cancer treatment. However, their development is challenged by the limited expansion and differentiation of the cells ex vivo. Here we induced the endogenous expansion and activation of γδ T cells through oral administration of garlic-derived nanoparticles (GNPs). We found that GNPs could significantly promote the proliferation and activation of endogenous γδ T cells in the intestine, leading to generation of large amount of interferon-γ (IFNγ). Moreover GNP-treated mice showed increased levels of chemokine CXCR3 in intestinal γδ T cells, which can drive their migration from the gut to the tumour environment. The translocation of γδ T cells and IFNγ from the intestine to extraintestinal subcutaneous tumours remodels the tumour immune microenvironment and synergizes with anti-PD-L1, inducing robust antitumour immunity. Our study delineates mechanistic insight into the complex gut-tumour interactome and provides an alternative approach for γδ T cell-based immunotherapy.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Garlic and Onion Studies · Immune Cell Function and Interaction · Immunotherapy and Immune Responses
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (40)
Show source-provided references
1. Duke-Cohan, J. S. et al. Pre-T cell receptor self-MHC sampling restricts thymocyte dedifferentiation. Nature 613, 565–574 (2023).10.1038/s41586-022-05555-7 ↗
2. Silva-Santos, B. & Mensurado, S. γδ T cells maintain sensitivity to immunotherapy in MHC-I-deficient tumors. Nat. Immunol. 24, 387–388 (2023).10.1038/s41590-023-01429-w ↗
3. de Vries, N. L. et al. γδ T cells are effectors of immunotherapy in cancers with HLA class I defects. Nature 613, 743–750 (2023).10.1038/s41586-022-05593-1 ↗
4. Rancan, C. et al. Exhausted intratumoral Vδ2− γδ T cells in human kidney cancer retain effector function. Nat. Immunol. 24, 612–624 (2023).10.1038/s41590-023-01448-7 ↗
5. Zhu, X. et al. Dectin-1 signaling on colonic γδ T cells promotes psychosocial stress responses. Nat. Immunol. 24, 625–636 (2023).10.1038/s41590-023-01447-8 ↗
6. Wu, Y. et al. An innate-like Vδ1 + γδ T cell compartment in the human breast is associated with remission in triple-negative breast cancer. Sci. Transl. Med. 11, eaax9364 (2019).10.1126/scitranslmed.aax9364 ↗
7. Mensurado, S., Blanco-Domínguez, R. & Silva-Santos, B. The emerging roles of γδ T cells in cancer immunotherapy. Nat. Rev. Clin. Oncol. 20, 178–191 (2023).10.1038/s41571-022-00722-1 ↗
8. De Gassart, A. et al. Development of ICT01, a first-in-class, anti-BTN3A antibody for activating Vγ9Vδ2 T cell-mediated antitumor immune response. Sci. Transl. Med. 13, eabj0835 (2021).10.1126/scitranslmed.abj0835 ↗
9. Nishimoto, K. P. et al. Allogeneic CD20‐targeted γδ T cells exhibit innate and adaptive antitumor activities in preclinical B‐cell lymphoma models. Clin. Transl. Immunol. 11, e1373 (2022).10.1002/cti2.1373 ↗
10. Xu, Y. et al. Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer. Cell. Mol. Immunol. 18, 427–439 (2021).10.1038/s41423-020-0515-7 ↗
11. Dwivedi, S. F. V. P. Allicin as an adjunct immunotherapy against tuberculosis. J. Cell. Immunol. 2, 78–182 (2020).
12. Li, Z. et al. Allicin shows antifungal efficacy against Cryptococcus neoformans by blocking the fungal cell membrane. Front. Microbiol. 13, 1012516 (2022).10.3389/fmicb.2022.1012516 ↗
13. Catanzaro, E., Canistro, D., Pellicioni, V., Vivarelli, F. & Fimognari, C. Anticancer potential of allicin: a review. Pharmacol. Res. 177, 106118 (2022).10.1016/j.phrs.2022.106118 ↗
14. Nantz, M. P. et al. Supplementation with aged garlic extract improves both NK and γδ-T cell function and reduces the severity of cold and flu symptoms: a randomized, double-blind, placebo-controlled nutrition intervention. Clin. Nutr. 31, 337–344 (2012).10.1016/j.clnu.2011.11.019 ↗
15. Goodridge, H. S. et al. Activation of the innate immune receptor dectin-1 upon formation of a ‘phagocytic synapse’. Nature 472, 471–475 (2011).10.1038/nature10071 ↗
16. Iliev, I. D. et al. Interactions between commensal fungi and the C-type lectin receptor dectin-1 influence colitis. Science 336, 1314–1317 (2012).10.1126/science.1221789 ↗
17. Taylor, P. R. et al. Dectin-1 is required for β-glucan recognition and control of fungal infection. Nat. Immunol. 8, 31–38 (2007).10.1038/ni1408 ↗
18. Petermann, F. et al. γδ T cells enhance autoimmunity by restraining regulatory T cell responses via an interleukin-23-dependent mechanism. Immunity 33, 351–363 (2010).10.1016/j.immuni.2010.08.013 ↗
19. Price, S. J. & Hope, J. C. Enhanced secretion of interferon-γ by bovine γδ T cells induced by coculture with Mycobacterium bovis-infected dendritic cells: evidence for reciprocal activating signals. Immunology 126, 201–208 (2009).10.1111/j.1365-2567.2008.02889.x ↗
20. Sedlak, C., Patzl, M., Saalmuller, A. & Gerner, W. IL-12 and IL-18 induce interferon-γ production and de novo CD2 expression in porcine γδ T cells. Dev. Comp. Immunol. 47, 115–122 (2014).10.1016/j.dci.2014.07.007 ↗
21. Teo, H. Y. et al. IL-12/18/21 pre-activation enhances the anti-tumor efficacy of expanded γδT cells and overcomes resistance to anti-PD-L1 treatment. Cancer Immunol. Res. 11, 978–999 (2022).10.1158/2326-6066.CIR-21-0952 ↗
22. Beziaud, L. et al. IFNγ-induced stem-like state of cancer cells as a driver of metastatic progression following immunotherapy. Cell Stem Cell 30, 818–831.e816 (2023).10.1016/j.stem.2023.05.007 ↗
23. Kohlgruber, A. C. et al. γδ T cells producing interleukin-17A regulate adipose regulatory T cell homeostasis and thermogenesis. Nat. Immunol. 19, 464–474 (2018).10.1038/s41590-018-0094-2 ↗
24. Yong, L. et al. Calcium/calmodulin-dependent protein kinase IV promotes imiquimod-induced psoriatic inflammation via macrophages and keratinocytes in mice. Nat. Commun. 13, 4255 (2022).10.1038/s41467-022-31935-8 ↗
25. Nielsen, M. M., Witherden, D. A. & Havran, W. L. γδ T cells in homeostasis and host defence of epithelial barrier tissues. Nat. Rev. Immunol. 17, 733–745 (2017).10.1038/nri.2017.101 ↗
26. Bagheri, H. et al. CXCL-10: a new candidate for melanoma therapy? Cell Oncol. 43, 353–365 (2020).10.1007/s13402-020-00501-z ↗
27. House, I. G. et al. Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade. Clin. Cancer Res. 26, 487–504 (2020).10.1158/1078-0432.CCR-19-1868 ↗
28. Karin, N. CXCR3 ligands in cancer and autoimmunity, chemoattraction of effector T cells, and beyond. Front. Immunol. 11, 976 (2020).10.3389/fimmu.2020.00976 ↗
29. Ozga, A. J. et al. CXCL10 chemokine regulates heterogeneity of the CD8+ T cell response and viral set point during chronic infection. Immunity 55, 82–97 e88 (2022).10.1016/j.immuni.2021.11.002 ↗
30. Silva-Santos, B., Serre, K. & Norell, H. γδ T cells in cancer. Nat. Rev. Immunol. 15, 683–691 (2015).10.1038/nri3904 ↗
31. Grasso, C. S. et al. Conserved interferon-γ signaling drives clinical response to immune checkpoint blockade therapy in melanoma. Cancer Cell 38, 500–515 e503 (2020).10.1016/j.ccell.2020.08.005 ↗
32. Larson, R. C. et al. CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours. Nature 604, 563–570 (2022).10.1038/s41586-022-04585-5 ↗
33. Abiko, K. et al. IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br. J. Cancer 112, 1501–1509 (2015).10.1038/bjc.2015.101 ↗
34. Papadopoulou, M., Sanchez Sanchez, G. & Vermijlen, D. Innate and adaptive γδ T cells: how, when, and why. Immunol. Rev. 298, 99–116 (2020).10.1111/imr.12926 ↗
35. Bordon, Y. γδ T cells mediate immunotherapy responses when cancers lack MHC class I. Nat. Rev. Immunol. 23, 137 (2023).10.1038/s41577-023-00842-4 ↗
36. Lien, S. C. et al. Tumor reactive γδ T cells contribute to a complete response to PD-1 blockade in a Merkel cell carcinoma patient. Nat. Commun. 15, 1094 (2024).10.1038/s41467-024-45449-y ↗
37. Xu, J. et al. Yeast-derived nanoparticles remodel the immunosuppressive microenvironment in tumor and tumor-draining lymph nodes to suppress tumor growth. Nat. Commun. 13, 110 (2022).10.1038/s41467-021-27750-2 ↗
38. Fan, Q. et al. An implantable blood clot-based immune niche for enhanced cancer vaccination. Sci. Adv. 6, eabb4639 (2020).10.1126/sciadv.abb4639 ↗
39. Han, X. et al. Red blood cell-derived nanoerythrosome for antigen delivery with enhanced cancer immunotherapy. Sci. Adv. 5, eaaw6870 (2019).10.1126/sciadv.aaw6870 ↗
40. Zhu, H. et al. Human PBMC scRNA-seq-based aging clocks reveal ribosome to inflammation balance as a single-cell aging hallmark and super longevity. Sci. Adv. 9, eabq7599 (2023).10.1126/sciadv.abq7599 ↗